Ultimovacs ASA: Share capital increase related to exercise of options
September 05, 2022 10:30 ET
|
Ultimovacs ASA
Oslo, 05 September 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 4,400 through the issuance of 44,000 new shares, each with...
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
August 22, 2022 11:00 ET
|
Ultimovacs ASA
Will cover methods for eliciting T cell immune responseProtects US sales and marketing of UV1 Oslo, August 22, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in...
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
August 19, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results today. The presentation by...
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
August 18, 2022 02:00 ET
|
Ultimovacs ASA
The TENDU interim safety results from nine patients show no safety concernsTrial extended to enroll up to three additional patients at the highest dose levelTENDU designed to evaluate the...
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
August 12, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, 12 August 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second quarter 2022 results...
Ultimovacs ASA: Mandatory notification of trade by primary insider
June 30, 2022 07:20 ET
|
Ultimovacs ASA
Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK...
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
June 30, 2022 02:00 ET
|
Ultimovacs ASA
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free...
Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
June 20, 2022 02:00 ET
|
Ultimovacs ASA
30 patients treated with UV1/pembrolizumab24-month survival rate of 73%Promising survival data follows encouraging clinical response rates and good safety Oslo, 20 June 2022: Ultimovacs...
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
May 25, 2022 12:45 ET
|
Ultimovacs ASA
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 yearsUV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint...
Ultimovacs ASA: First quarter 2022 result presentation
May 12, 2022 02:00 ET
|
Ultimovacs ASA
Oslo, 12 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today. The presentation by...